Revance Logo
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
ABOUTLEADERSHIPBOARDPARTNERSHIPS
SUSTAINABILITYMEDICAL EDUCATIONAL GRANTSINVESTIGATOR SPONSORED TRIALS
Company
INVESTOR RELATIONSPRESS RELEASESEVENTS + PRESENTATIONSFINANCIALS & FILINGSCORPORATE GOVERNANCE
STOCK INFORMATIONANALYST COVERAGEINVESTOR FAQSCONTACT US
Investors
OPPORTUNITIESCULTUREBENEFITS
Careers
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
Facebook logoInstagram logoTwitter logoLinkedIn logo
1222 Demonbreun St
20th Floor
Nashville, TN 37203
+1 (510) 742-3400
LoginContact Revance
Back
February 5, 2014
Revance Therapeutics Announces Pricing of Initial Public Offering
April 2, 2013
Revance Therapeutics Announces $33 Million Series E Financing
March 25, 2013
Revance Therapeutics Announces Appointment of Lauren Silvernail as Chief Financial Officer
October 8, 2012
Revance Therapeutics Regains All Worldwide Rights To Its Botulinum Toxin Products
June 10, 2011
Revance Announces $45 Million Financing
October 22, 2010
Revance Therapeutics Announces Clinical Trial Results of RT001 Topical Gel Presented at the Annual Meeting of the American Society of Dermatologic Surgery
January 4, 2010
Revance Annouces Series D Financing
July 28, 2009
Medicis and Revance Announce Agreement for Development of Next-Gen Neurotoxin
July 9, 2009
Revance Announces Efficacy of Topical Botulinum Toxin Type A for the Treatment of Facial Wrinkles
November 18, 2008
Revance Secures $8 Million in New Financing
Displaying 271 - 280 of 280